RP
SGMO

Raiff Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Raiff Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-85,000
Closed -$1.29M – 51
2014
Q4 		$1.29M Buy
+85,000
New +$1.03M 1.05% 27

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Raiff Partners's SGMO Position: Q1 2015 in Review

Raiff Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2015, closing a stake of 85,000 shares — an estimated $1.29M sold.

Raiff Partners first reported a position in SGMO in Q4 2014 and held it in 1 quarter. The position peaked at $1.29M in Q4 2014. 171 funds tracked by Wall St. Rank hold SGMO as of Q1 2015.

  • Raiff Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2015 after selling out during the quarter.
  • Raiff Partners sold 85,000 SANGAMO THERAPEUTICS INC shares in Q1 2015, an estimated $1.29M.
  • Raiff Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 1 quarter.
  • Raiff Partners's SANGAMO THERAPEUTICS INC position peaked at $1.29M in Q4 2014.
  • 171 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2015.

Based on Raiff Partners's 13F filing for Q1 2015, filed 14 May 2015.